Bioharvest Sciences (BHST) Current Deferred Revenue (2023 - 2025)

Bioharvest Sciences has reported Current Deferred Revenue over the past 3 years, most recently at $492000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $492000.0 for Q4 2025, down 45.7% from a year ago — trailing twelve months through Dec 2025 was $492000.0 (down 45.7% YoY), and the annual figure for FY2025 was $492000.0, down 45.7%.
  • Current Deferred Revenue for Q4 2025 was $492000.0 at Bioharvest Sciences, down from $906000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for BHST hit a ceiling of $906000.0 in Q4 2024 and a floor of $492000.0 in Q4 2025.
  • Median Current Deferred Revenue over the past 3 years was $718000.0 (2023), compared with a mean of $705333.3.
  • Biggest five-year swings in Current Deferred Revenue: grew 26.18% in 2024 and later plummeted 45.7% in 2025.
  • Bioharvest Sciences' Current Deferred Revenue stood at $718000.0 in 2023, then grew by 26.18% to $906000.0 in 2024, then plummeted by 45.7% to $492000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $492000.0 (Q4 2025), $906000.0 (Q4 2024), and $718000.0 (Q4 2023) per Business Quant data.